Segura-Duch Gloria, Oliver-Gutierrez David, Duch Susana, Schilt Mar, Arciniegas-Perasso Carlos
Ophthalmology, Verte-ICO Oftalmología, Barcelona, Spain.
Oftalmology, Centro de Oftalmología Barraquer, Barcelona, Spain.
BMJ Open Ophthalmol. 2025 Feb 13;10(1):e001879. doi: 10.1136/bmjophth-2024-001879.
Different aqueous restrictive manoeuvres in non-valved devices affect intraocular pressure (IOP) levels in the first postoperative month. This study compares tube ligature (TL) alone to TL plus rip cord stent (TLS) on the efficacy of the Baerveldt 350.
We conducted a retrospective consecutive case-series observational study to assess efficacy by measuring IOP, success rates and the reduction of antiglaucoma medication usage over 3 years.
The study included 43 eyes in the TL group and 29 in the TLS group. Initial IOPs were 26.67 mm Hg for TL and 28.21 mm Hg for TLS. After 1 year, IOP decreased to 13.03 mm Hg and 12.11 mm Hg, respectively. Over 3 years, TLS consistently achieved greater reductions in IOP compared with TL, with significant differences of 3.56 mm Hg in the second year (p=0.01) and 3.34 mm Hg in the third year (p=0.01). Mean antiglaucoma medication use decreased from 3.03 (SD 1.29) to 0.72 (SD 0.47) over 3 years, representing a 76.24% reduction, with no differences between the TL and TLS groups. Failure rate at 1 year was significantly lower for TLS under the success criteria of IOP=(6-18) mm Hg (TL: 33.33%, TLS: 7.14%, p=0.02). Rates of transient hypotension and hypertensive phase were higher in the TL group: 93.02% vs 34.48% (p<0.001) and 58.14% vs 32.14% (χ²=4.59, p=0.03), respectively.
Adding the rip cord stent to the Baerveldt implant significantly enhances long-term IOP control and reduces failure rates compared with TL alone. The lower incidence of hypertensive phases could be due to sequential tube opening. Small sample size, lack of randomisation and follow-up discrepancies may introduce bias and limit statistical power, highlighting the need for further research to confirm these conclusions.
非瓣膜装置中不同的水相限制操作会影响术后第一个月的眼压(IOP)水平。本研究比较了单独使用管结扎术(TL)与TL加撕裂索支架(TLS)对Baerveldt 350疗效的影响。
我们进行了一项回顾性连续病例系列观察研究,通过测量眼压、成功率和3年内抗青光眼药物使用的减少情况来评估疗效。
该研究包括TL组的43只眼和TLS组的29只眼。TL组的初始眼压为26.67 mmHg,TLS组为28.21 mmHg。1年后,眼压分别降至TL组13.03 mmHg和TLS组12.11 mmHg。在3年期间,与TL相比,TLS持续实现了更大幅度的眼压降低,第二年差异显著,为3.56 mmHg(p = 0.01),第三年为3.34 mmHg(p = 0.01)。3年内抗青光眼药物的平均使用量从3.03(标准差1.29)降至0.72(标准差0.47),降幅为76.24%,TL组和TLS组之间无差异。在眼压=(6 - 18)mmHg的成功标准下,TLS组1年时的失败率显著低于TL组(TL组:33.33%,TLS组:7.14%,p = 0.02)。TL组的短暂性低血压和高血压期发生率更高:分别为93.02%对34.48%(p < 0.001)和58.14%对32.14%(χ² = 4.59,p = 0.03)。
与单独使用TL相比,在Baerveldt植入物中添加撕裂索支架可显著增强长期眼压控制并降低失败率。高血压期发生率较低可能是由于管的顺序开放。样本量小、缺乏随机化和随访差异可能会引入偏差并限制统计效力,这突出了需要进一步研究以证实这些结论。